0.00Open4.20Pre Close0 Volume0 Open Interest2.00Strike Price0.00Turnover711.84%IV8.20%PremiumAug 16, 2024Expiry Date3.73Intrinsic Value100Multiplier25DDays to Expiry0.47Extrinsic Value100Contract SizeAmericanOptions Type0.9336Delta0.0119Gamma1.23Leverage Ratio-0.0277Theta0.0005Rho1.15Eff Leverage0.0020Vega
Annexon Stock Discussion
Annexon to Present Additional Phase 2 Data Showing Preservation of Visual Function and Structure by ANX007 in Geographic Atrophy at the 42nd ASRS Annual Scientific Meeting
Annexon will present additional data from its Phase 2 ARCHER trial on ANX007 at the 42nd ASRS Annual Scientific Meeting in Stockholm, Sweden from July 17-20, 2024. The presentations will highlight the protective effects of ANX007 on visual acuity and anatomical measures in patients with geographic atroph...
Annexon Presented Additional Positive Phase 3 Results for Anx005 C1Q-Targeted Immunotherapy in Guillain-Barré Syndrome at the 2024 Pns Annual Meeting
Annexon Presented Additional Positive Phase 3 Results for ANX005 C1q-Targeted Immunotherapy in Guillain-Barré Syndrome at the 2024 PNS Annual Meeting
Annexon announced positive results from its Phase 3 trial of ANX005, an immunotherapy targeting C1q for Guillain-Barré Syndrome (GBS). Presented at the 2024 PNS Annual Meeting, data showed faster and more complete recovery for ANX005-treated patients compared to placebo.
Significant improvements were noted in primary and mult...
No comment yet